登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06716164,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
19 岁 至 70 岁;性别:不限
登记记录的入选字段
At least one measurable lesion at baseline, according to the Preliminary Assessment, staging and Response Assessment recommendations for Hodgkin's and non-Hodgkin's lymphoma (2014 edition);
入选标准第 10 条
After treatment with these regimens, patients maintain SD (SD duration ≤ 12 months) or still progress;
入选标准第 5 条
If the subject has progressed or relapsed after prior CD19 CAR-T cell therapy, the planned apheresis phase should be at least 1 month after that, or the subject has been treated with other biologics, but is in the washout period;
入选标准第 9 条
Complete blood count (CBC) test [the following criteria should be met within 24 hours prior to apheresis, and supportive treatment such as transfusion, platelet transfusion, cell growth factor (except recombinant erythropoietin) should be avoided within 7 days prior to detection]
入选标准第 14 条
Patients who had received chemotherapy other than preconditioning chemotherapy within 2 weeks prior to Meta10-19 infusion;
排除标准第 2 条
Platelet count ≥ 25×109/L;
入选标准第 16 条
Hemoglobin ≥ 70.0 g/L
入选标准第 17 条
Serum creatinine (Scr) ≤ 1.5 x ULN, or
入选标准第 19 条
endogenous creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault formula);
入选标准第 20 条
alanine aminotransferase (ALT) ≤ 2.5 x ULN;
入选标准第 21 条
aspartate aminotransferase (AST) ≤ 2.5 ×ULN;
入选标准第 22 条
Total bilirubin (TBIL) ≤ 2 ×ULN; Subjects with total bilirubin < 3 × ULN and direct bilirubin < 1.5× ULN with Gilbert-.Meulengracht syndrome could be included;
入选标准第 23 条
Serum lipase and amylase ≤ 1.5×ULN;
入选标准第 24 条
Alkaline phosphatase (ALP) ≤ 2.5 ×ULN;
入选标准第 25 条
In case of bone or liver metastasis, AST, ALT and ALP ≤ 5 ×ULN;
入选标准第 26 条
Prothrombin time (PT) extended ≤ 4 s, fibrinogen ≥ 1 g/L, activated partial thromboplastin time (APTT) ≤ 1.5 ×ULN;
入选标准第 27 条
Patients with active hepatitis B (defined as hepatitis B surface antigen positive or hepatitis B core antibody positive, concomitant hepatitis B virus DNA level > 1000 copies/ml) or hepatitis C (HCV RNA positive);
排除标准第 4 条
Patients with HIV antibody positive or treponema pallidum antibody positive;
排除标准第 5 条
Carcinoma in situ (DCIS) of cervical or breast cancer, which has been treated therapeutically, has shown no signs of recurrence for at least 3 years prior to the signing of the informed consent;
排除标准第 10 条
The primary malignancy has been completely resected and in complete remission for ≥5 years;
排除标准第 11 条
Women of childbearing age and all male patients must consent to use a effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR T cells in vivo.
入选标准第 36 条
Women who are pregnant or breastfeeding (pregnancy tests for women of childbearing age are positive);
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06716164,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
All subjects or guardians must sign an informed consent form approved by the Ethics Committee in person before commencing any screening process; Age > 18 years old, ≤ 70 years old, male or female; Diagnosis of relapsed/refractory (R/R) indolent B-cell lymphoma, and/or R/R diffuse large B-cell lymphoma (DLBCL). Refractory diseases are defined as one of the following: Patients with relapsed or refractory B-cell lymphoma treated with one standard treatment regimen and one salvage regimen treated with rituximab or another CD20 antibody drug and at least two treatment regiments appropriate for their disease, one of which should include anthracyclines; After treatment with these regimens, patients maintain SD (SD duration ≤ 12 months) or still progress; Recurrence after autologous hematopoietic stem cell transplantation, or recurrence of allogeneic HSCT, or inability to accept HSCT for various reasons; Patients with double-strike or triple-strike B-cell lymphoma who did not respond to second-line therapy; CD19 expression was positive by immunohistochemistry or flow cytometry (accept the results of this peripheral blood mononuclear cells or previous report from a Class A tertiary hospital before peripheral blood collection); If the subject has progressed or relapsed after prior CD19 CAR-T cell therapy, the planned apheresis phase should be at least 1 month after that, or the subject has been treated with other biologics, but is in the washout period; At least one measurable lesion at baseline, according to the Preliminary Assessment, staging and Response Assessment recommendations for Hodgkin's and non-Hodgkin's lymphoma (2014 edition); Expected survival time greater than 12 weeks; ECOG score 0-1 (subjects with central nervous system diseases caused by leukemia or lymphoma need to be determined by the investigator); Organ function: Complete blood count (CBC) test [the following criteria should be met within 24 hours prior to apheresis, and supportive treatment such as transfusion, platelet transfusion, cell growth factor (except recombinant erythropoietin) should be avoided within 7 days prior to detection] Lymphocyte count ≥ 0.5×109/L (except for those receiving bridging chemotherapy); Platelet count ≥ 25×109/L; Hemoglobin ≥ 70.0 g/L Blood Biochemistry: Serum creatinine (Scr) ≤ 1.5 x ULN, or endogenous creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault formula); alanine aminotransferase (ALT) ≤ 2.5 x ULN; aspartate aminotransferase (AST) ≤ 2.5 ×ULN; Total bilirubin (TBIL) ≤ 2 ×ULN; Subjects with total bilirubin < 3 × ULN and direct bilirubin < 1.5× ULN with Gilbert-.Meulengracht syndrome could be included; Serum lipase and amylase ≤ 1.5×ULN; Alkaline phosphatase (ALP) ≤ 2.5 ×ULN; In case of bone or liver metastasis, AST, ALT and ALP ≤ 5 ×ULN; Prothrombin time (PT) extended ≤ 4 s, fibrinogen ≥ 1 g/L, activated partial thromboplastin time (APTT) ≤ 1.5 ×ULN; Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) > 91% in indoor air environment.. Hemodynamic stability was determined by echocardiography or multichannel radionuclide angiography (MUGA) and LVEF ≥45%; Patients using the following drugs must meet the following conditions: Steroid: Therapeutic doses of steroids must be discontinued 2 weeks prior to Meta10-19 infusion. However, physiological replacement doses of steroids are permitted, hydrocortisone or its equivalent < 6-12mg/mm2/ day; Immunosuppressive agent: Any immunosuppressive drug must be stopped ≥4 weeks before the informed consent is signed; Stop all anti-proliferation therapies other than preconditioning chemotherapy in the 2 weeks before Meta10-19 infusion; Treatment for CNS disease must be stopped 1 week before Meta10-19 infusion (e.g., intrathecal methotrexate) The patient has recovered from the toxicity of the previous treatment, that is, the CTCAE toxicity grade is less than 1 (The exception is specific toxicity of grade 2 or less, such as hair loss, which the researchers have determined is not recoverable in a short period of time) is suitable for pretreatment chemotherapy and CAR-T cell therapy; Women of childbearing age and all male patients must consent to use a effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR T cells in vivo.排除标准:Exclusion Criteria:
Patients with present or history of central nervous system diseases not associated with leukemia or lymphoma, such as seizures disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement; Patients who had received chemotherapy other than preconditioning chemotherapy within 2 weeks prior to Meta10-19 infusion; Patients who participated in other clinical trials within 30 days prior to enrollment; Patients with active hepatitis B (defined as hepatitis B surface antigen positive or hepatitis B core antibody positive, concomitant hepatitis B virus DNA level > 1000 copies/ml) or hepatitis C (HCV RNA positive); Patients with HIV antibody positive or treponema pallidum antibody positive; Patients with uncontrolled acute life-threatening bacterial, viral or fungal infections (e.g. positive blood cultures ≤72 hours before Meta10-19 infusion); History of unstable angina and/or myocardial infarction within 6 months prior to signing the informed consent; History of uncontrolled thrombotic events, major bleeding, or deep venous thrombosis (DVT) within 12 months prior to signing the informed consent; Patients with history of other malignancies, but the following conditions can be enrollment: Adequately treated basal or squamous cell carcinoma (requiring adequate wound healing before signing informed consent); Carcinoma in situ (DCIS) of cervical or breast cancer, which has been treated therapeutically, has shown no signs of recurrence for at least 3 years prior to the signing of the informed consent; The primary malignancy has been completely resected and in complete remission for ≥5 years; Women who are pregnant or breastfeeding (pregnancy tests for women of childbearing age are positive); History of QT interval prolongation or severe cardiac disease; Before signing the informed consent form, the ADA (FMC63) test was significantly positive (the test result was weakly positive, and it was necessary to discuss with the investigator whether to rule it out); Other conditions that the investigator considered should not be enrolled in this clinical study.
引自 ClinicalTrials.gov, NCT06716164, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06716164,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。